CADTH | Evidence Driven
CADTH | Evidence Driven

Nab-paclitaxel

Details

Files
Generic Name:
Nab-paclitaxel
Project Status:
Active
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0354-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
​In combination with gemcitabine, for previously treated advanced (locally advanced unresectable or metastatic) pancreatic cancer
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open02-Jan-24
Call for patient/clinician input closed26-Feb-24
Call for industry input open02-Jan-24
Call for industry input closed26-Feb-24
Submission received21-Dec-23

Files

Proposed Project Scope View PDF

Related Content

Last Updated : March 8, 2024